Other research teams have reported high correlations between low ERCC1 expression and in vitro sensitivity to cisplatin in malignant cervical cancer cell lines [16,17], testicular cancer [18], and malignant effusions collected from non-small cell lung cancer patients [19,20]. This evidence concerns the gene ERCC1 and cervical carcinoma.